ClinicalTrials.gg
RecruitingNCT05848167Updated Nov 22, 2023

Senile Osteoporotic Fractures Cohort Study(SOFCS)

An observational study in Osteoporotic Fractures, sponsored by Suzhou Municipal Hospital. Recruiting at 1 site in China. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-22.

Sponsored by Suzhou Municipal Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 6 months ago, but the record still lists the study as recruiting.
  • Started Jul 2021; still recruiting 5 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Osteoporotic Fractures with a site in China — 7 open to participants now, 8 under way, none of them phase 3. Osteoporotic Fractures · China.

Started
2021
with 2 others
Observational
5 of 13
2 open now
Registered
8th of 13
by date
Lead sponsor
1 of 13
Suzhou Municipal Hospital

Among the 13 studies in Osteoporotic Fractures with a site in China, this one is one of 3 that started in 2021, is one of 5 observational ones, and was the 8th registered.

Osteoporotic Fractures

87 studies on the registry are indexed under Osteoporotic Fractures; 22 are open to participants now.

Browse Osteoporotic Fractures studies →

Open to participants now

7 of the 13 studies in Osteoporotic Fractures with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 14 Osteoporotic Fractures studies recruiting now, 9 (64%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Osteoporotic Fractures with a site in China, or all of them as a file.
02

Study summary

Osteoporotic fracture is one of the main causes of disability and death in elderly patients. Specific disease cohort study is an important basis for accurate prevention and treatment of senile osteoporotic fractures. Investigators plan to collect and manage the baseline and clinical information of more than 2000 elderly patients with osteoporotic fractures after surgery through the platform of special disease collaborative prevention and treatment system and medical record database of Suzhou Municipal Hospital in two years, and carry out short-term and long-term follow-up observation.

Read the detailed description

Osteoporotic fracture is one of the main causes of disability and death in elderly patients. Compared with patients with no history of fractures, the risk of a second fracture after an initial fracture doubled, with a fatality rate of up to 34.8%. There has been a lot of progress in the diagnosis and treatment of osteoporotic fractures in the elderly. However, there are few reports on the diagnosis and treatment of osteoporotic fractures in the elderly after surgery. Based on previous studies, it is found that the re-fracture after operation of osteoporotic fracture in the elderly is not only directly caused by the fall, but also caused by the interaction of multiple risk factors including environmental factors, physiological factors and neuroskeletal musculoskeletal system. Therefore, it is of great significance to break the traditional diagnosis and treatment mode, improve the diagnosis and treatment effect, and save medical resources to carry out research on the disease characteristics, rules and risk warning after senile osteoporotic fracture operation. Specific disease cohort study is an important basis for accurate prevention and treatment of senile osteoporotic fractures. Investigators plan to collect and manage the baseline and clinical information of more than 2000 elderly patients with osteoporotic fractures after surgery through the platform of special disease collaborative prevention and treatment system and medical record database of Suzhou Municipal Hospital in two years, and carry out short-term and long-term follow-up observation.

03

Conditions studied

  • Osteoporotic Fractures

Browse trials for

Keywords

  • Senile osteoporotic fracture,Cohort study,mechanism,outcome
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Elderly patients after operation of osteoporotic fracture.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥65 years old
  2. Patients with osteoporosis
  3. No gender limitation

Exclusion criteria

Exclusion Criteria:

  1. \< 65 years old;
  2. Non-osteoporotic fracture;
  3. Alzheimer's disease;
  4. Bone tumors.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Bone mineral density

    BMD

    Time frame: two years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2021 (actual). Primary completion is estimated for May 2024, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2023
First posted
May 8, 2023
StartActual
Jul 15, 2021
Primary completionEst.
May 14, 2024
CompletionEst.
Jul 14, 2024
Last update
Nov 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05848167
Lead sponsor
Suzhou Municipal Hospital
Responsible party
Mo Zhou (Director, Suzhou Municipal Hospital) — Principal investigator
First posted
May 8, 2023
Start date
Jul 15, 2021
Primary completion
May 14, 2024 (estimated)
Completion
Jul 14, 2024 (estimated)
Last update
Nov 22, 2023

Study contacts

Hao Y feng, doctor
Contact
13913109339@163.com
13913109339
Che Y jun, doctor
Contact
cheyanjun1980@hotmail.com
19941919699
Hao Y feng, doctor
study chair · Suzhou Municipal Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion